Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
38 hedge funds and large institutions have $23.7M invested in Catalyst Pharmaceutical in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 4 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
100% more call options, than puts
Call options by funds: $8K | Put options by funds: $4K
31% more capital invested
Capital invested by funds: $18.1M → $23.7M (+$5.57M)
19% more funds holding
Funds holding: 32 → 38 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.19M |
| 2 |
SC
Sophrosyne Capital
New York
|
+$591K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$420K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$209K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$303K |
| 2 |
Jane Street
New York
|
-$83K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$33.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$24.8K |
| 5 |
TAM
Telluride Asset Management
Wayzata,
Minnesota
|
-$22K |
CPRX Hedge Fund Activity: Q1 2014 in Review
38 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2014, worth a combined $23.7M — up 31% from $18.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CPRX positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.19M. The largest seller was Zacks Investment Management, exiting entirely with an estimated $303K sold.
- 38 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2014, up from 32 in Q4 2013.
- Funds reported $23.7M of Catalyst Pharmaceutical stock for Q1 2014, up 31% quarter-over-quarter.
- 10 funds opened new Catalyst Pharmaceutical positions in Q1 2014 and 4 closed out, a net change of +6 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2014 was Baker Bros. Advisors, an estimated $1.19M added.
- The largest Catalyst Pharmaceutical seller in Q1 2014 was Zacks Investment Management, an estimated $303K sold.
Based on aggregated 13F filings for Q1 2014.